Please assess the completion status of the following clinical trial:

Trial Title: Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged between 18 years and 75 years included~* ECOG (Eastern Cooperative Oncology Group) Performance Status ≤ 2~* Primary (pseudomyxoma peritonei, peritoneal mesothelioma) or Secondary (colorectal or ovarian) peritoneal malignancies~* Curative intent resection obtained by a complete resection according to the Completeness of Cytoreduction score (CC) (CC 0-1) followed by HIPEC Different intraperitoneal drug administration modalities such as neoadjuvant systemic plus simultaneous intraperitoneal and intravenous chemotherapy (NIPS) or pressurized intra-peritoneal aerosol chemotherapy (PIPAC) does not represent exclusion criteria.~* Absence of extra-peritoneal metastatic disease or limited hepatic or lung metastases easily amenable to curative-intent resection or ablation~* Intraoperative Peritoneal Cancer Index (PCI score) ≥ 10~* Visceral resection with at least one digestive anastomosis with or without loop ileostomy or pancreatic or biliary resection.~* Negative serum pregnancy test for women of childbearing potential within 7 days prior to therapy~* Sexually active women of childbearing potential must agree to use a highly effective method of contraception or to abstain from sexual activity during the study and for 3 months after the last study treatment administration. Sexually active males patients must agree to use condom or to abstain from sexual activity during the study and for 3 months after the last study treatment administration. Also, it is recommended their women of childbearing potential partner use a highly effective method of contraception during the same period.~* Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.~* Patients must be affiliated to a social security system or beneficiary of the same~Exclusion Criteria:~* Macroscopically incomplete surgical resection (CC 2)~* Standard contraindications to pasireotide:~  1. patients with uncontrolled diabetes mellitus or a fasting plasma glucose \> 250mg/dl (14 mMol/L)~ 2. patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia including a corrected QT (QTc) interval longer than 450 msec, advanced heart block or a history of acute myocardial infarction within the six months preceding enrollment~ 3. patients with liver disease such as severe hepatic impairment (Child Pugh C), chronic active hepatitis or chronic persistent hepatitis with abnormal coagulation (INR\>1.5).~ 4. patients with the presence of active or suspected acute or chronic uncontrolled infection~ 5. hypersensitivity to somatostatin analogues or any component of pasireotide formulations~ 6. patients with uncontrolled hypothyroidism~* Patients participating or who have participated to another study evaluating the effect of a new drug other than pasireotide within 1 month prior to dosing~* Patient who have already participated to this study (a patient can only be included once in the study)~* Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will be unable to complete the entire study.~* Women who are pregnant or likely to be so, or who are breastfeeding~* Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pasireotide (Type: EXPERIMENTAL): 0.9 mg of pasireotide subcutaneously (s.c.) twice daily (14 doses) every 12 +/- 2 hours
- Placebo (Type: PLACEBO_COMPARATOR): 0.9 ml of saline water s.c. twice daily (14 doses) every 12 +/- 2 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).